NASDAQ:LEXX

Lexaria Bioscience Q4 2024 Earnings Results & Report

Lexaria Bioscience logo
$4.26 -0.15 (-3.31%)
As of 09:54 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Lexaria Bioscience missed analyst earnings expectations in its Q4 2024 results, released November 26, 2024. The company reported EPS of -$2.25 versus the -$1.65 consensus estimate.

Earnings Announcement Details

Quarter
Q4 2024
Time
During Market Hours
Conference Call
7:00 AM ET

Lexaria Bioscience EPS Results

Actual EPS
-$2.25
Consensus EPS
-$1.65
Beat/Miss
Missed by -$0.60
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Lexaria Bioscience Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Lexaria Bioscience's Q4 2026 earnings is estimated for Tuesday, November 24, 2026, based on past reporting schedules, with a conference call scheduled on Monday, November 23, 2026 at 12:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Lexaria Bioscience Q4 2024 Earnings FAQ

Lexaria Bioscience (NASDAQ:LEXX) reported earnings of -$2.25 per share for Q4 2024, missing the consensus estimate of -$1.65. The report was announced on Tuesday, November 26, 2024.

Lexaria Bioscience's next earnings date is estimated for Tuesday, November 24, 2026. MarketBeat tracks confirmed and estimated earnings dates for Lexaria Bioscience on the company's earnings history page.

Lexaria Bioscience Earnings Headlines

Lexaria Bioscience (LEXX) Projected to Release Earnings on Tuesday
Pentagon magnet restrictions take effect January 1, 2027
A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It would build and operate a rare earth processing facility on an active military base, with the Army receiving first right to production. The timing matters. New Pentagon restrictions on certain Chinese-origin rare earth magnets take effect January 1, 2027, while China controls more than 90% of global rare earth processing. The company's mine-to-magnet platform spans feedstock agreements, processing facilities, metallization technology, and downstream manufacturing, with initial commercial output targeted for 2027.tc pixel
LEXX: Introducing DehydraTECH 3.0
Lexaria Bioscience advances 12% on Australian tax rebate
See More Lexaria Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lexaria Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lexaria Bioscience and other key companies, straight to your email.

About Lexaria Bioscience

Lexaria Bioscience (NASDAQ:LEXX) is a biotechnology company developing DehydraTECH, a patented technology designed to improve the delivery and absorption of orally administered drugs and other active compounds. The platform incorporates active ingredients into a lipid-based formulation and is being studied for its potential to affect absorption and delivery characteristics.

The company’s research has explored applications in areas including hypertension, diabetes and weight management, epilepsy, and antiviral treatments. These programs are investigational; Lexaria’s work includes laboratory and clinical research rather than a broad portfolio of approved medicines.

Based in British Columbia, Canada, Lexaria focuses on developing and licensing its delivery technology and advancing research with pharmaceutical ingredients. The company has also developed consumer products in the past, including hemp-derived products, but its current activities center on DehydraTECH research and development.

View Lexaria Bioscience Profile